in Newswire January 19, 2022

NRx Pharmaceuticals Withheld COVID-19 Drug Approval Info from Investors, Class Action Alleges

Dal Bosco v. NRx Pharmaceuticals, Inc. et al.

Filed: January 18, 2022 § 1:22-cv-00066

A class action alleges NRx Pharmaceuticals was not forthcoming to investors with regard to the prospects of a purported COVID-19 treatment being approved for emergency use.



Last Updated on January 19, 2022 — 4:30 PM

Corrado Rizzi

Corrado Rizzi is the Managing Editor and a writer for

About is a group of online professionals (designers, developers and writers) with years of experience in the legal industry.

Learn More

Before commenting, please review our comment policy.